Sugi Predict

Sugi Predict / Targets / TMPRSS4

TMPRSS4

Transmembrane protease serine 4 · Q9NRS4 · TMPRSS4 on Sugi Atlas →

11,385 patent compounds predicted against TMPRSS4, 7,330 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Imd-0354 Imd-0354 (SCHEMBL129165) 1.00 16/20
SCHEMBL330059 SCHEMBL330059 0.90 16/20
SCHEMBL131758 SCHEMBL131758 0.85 16/20
SCHEMBL331507 SCHEMBL331507 0.72 16/20
SCHEMBL331631 SCHEMBL331631 1.00 15/20
SCHEMBL330413 SCHEMBL330413 1.00 14/20
SCHEMBL330282 SCHEMBL330282 0.83 14/20
SCHEMBL330225 SCHEMBL330225 0.79 14/20
SCHEMBL330394 SCHEMBL330394 0.79 14/20
SCHEMBL134080 SCHEMBL134080 0.77 14/20
SCHEMBL330301 SCHEMBL330301 0.74 14/20
SCHEMBL330371 SCHEMBL330371 0.68 14/20
SCHEMBL129707 SCHEMBL129707 1.00 13/20
SCHEMBL132474 SCHEMBL132474 1.00 13/20
SCHEMBL134235 SCHEMBL134235 1.00 13/20
SCHEMBL129638 SCHEMBL129638 0.90 13/20
SCHEMBL330023 SCHEMBL330023 0.83 13/20
SCHEMBL131425 SCHEMBL131425 0.77 13/20
SCHEMBL329995 SCHEMBL329995 0.73 13/20
SCHEMBL329948 SCHEMBL329948 0.71 13/20

Clinical trials — most relevant to TMPRSS4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease PHASE4COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 PHASE2/PHASE3UNKNOWN
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit PHASE3WITHDRAWN
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus PHASE2UNKNOWN
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer PHASE2COMPLETED
NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia PHASE2COMPLETED
The Impact of Camostat Mesilate on COVID-19 Infection PHASE1/PHASE2COMPLETED
Nebulised BromAc in Healthy Volunteers PHASE1COMPLETED
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications PHASE1UNKNOWN
Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) EARLY_PHASE1UNKNOWN
Hesperidin and Diosmin for Treatment of COVID-19 EARLY_PHASE1UNKNOWN
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19 EARLY_PHASE1UNKNOWN
Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID nanRECRUITING
Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study nanWITHDRAWN
MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients nanUNKNOWN
Seawater Nasal Wash to Relieve COVID-19 Nasal Symptoms and Reduce SARS-CoV-2 Viral Load. nanCOMPLETED
ACE2 Gender Differences in Stroke With COVID-19 nanCOMPLETED
PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort nanUNKNOWN
Periodontal Health in Post COVID-19 Patients nanUNKNOWN
Impact of the Genetic Polymorphism on COVID-19 in Egypt nanUNKNOWN
Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids nanWITHDRAWN
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity nanWITHDRAWN
Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV. nanUNKNOWN
Cardiac Injury in COVID-19: a Pathology Study nanUNKNOWN
COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX) nanCOMPLETED
Association Between Periodontitis and Coronavirus Disease (COVID-19) nanCOMPLETED
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features nanUNKNOWN
Anti-Androgen Treatment for COVID-19 nanCOMPLETED
COVID-19 Infection and Fetal-neonatal Outcomes nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TMPRSS4 binder may also engage these)

ProteinNameSimilarity
P57727 — 0.999 P57727 →
Q8VCA5 — 0.997 Q8VCA5 →
P49150 — 0.995 P49150 →
Q8K1T0 — 0.994 Q8K1T0 →
P33587 — 0.994 P33587 →
P31394 — 0.994 P31394 →
ST14 Suppressor of tumorigenicity 14 protein 0.992 landscape →
Q9JIQ8 — 0.992 Q9JIQ8 →
P56677 — 0.992 P56677 →
Q3UZ09 — 0.992 Q3UZ09 →
F7 Coagulation factor VII 0.991 landscape →
P29598 — 0.991 P29598 →
Q9GLP2 — 0.991 Q9GLP2 →
P00745 — 0.991 P00745 →
P04185 — 0.991 P04185 →
P11214 — 0.991 P11214 →
P18292 — 0.991 P18292 →
P98121 — 0.990 P98121 →
P19637 — 0.990 P19637 →
Q66TN7 — 0.990 Q66TN7 →
Q2F9P2 — 0.990 Q2F9P2 →
Q58L93 — 0.989 Q58L93 →
Q5R8J0 — 0.989 Q5R8J0 →
P97435 — 0.989 P97435 →
P70375 — 0.989 P70375 →
Q8MHY7 — 0.989 Q8MHY7 →
Q6IE64 — 0.989 Q6IE64 →
Q2KJ63 — 0.989 Q2KJ63 →
F11 Coagulation factor XI 0.989 landscape →
P79953 — 0.989 P79953 →